Challenges in the management of pulmonary tuberculosis: a continuous clinical problem

Symposium
Chairs: E. Panic (Sombor, Serbia and Montenegro), L. Casali (Terni, Italy)
Aims: At the end of the symposium, the audience should know more about specific new drugs and new regimens for the treatment of multi-drug resistant tuberculosis (MDR-TB), the use of antituberculosis drugs in patients with HIV/TB co-infection who are treated with highly active anti retroviral treatment (HAART), and the effectiveness of immunotherapy in the treatment of TB.

New immunologic tools for the diagnosis and therapy of tuberculosis P. Barnes (Tyler, United States of America)
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? P. D. O. Davies (Liverpool, United Kingdom)
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients F. Scano (Geneva, Switzerland)
Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? C. Saltini (Rome, Italy)